Position Stand on Androgen and Human Growth Hormone Use

Total Page:16

File Type:pdf, Size:1020Kb

Position Stand on Androgen and Human Growth Hormone Use POSITION STATEMENT POSITION STAND ON ANDROGEN AND HUMAN GROWTH HORMONE USE 1 2,3 4 4,5 JAY R. HOFFMAN, WILLIAM J. KRAEMER, SHALENDER BHASIN, THOMAS STORER, 1 6 7 8,9 NICHOLAS A. RATAMESS, G. GREGORY HAFF, DARRYN S. WILLOUGHBY, AND ALAN D. ROGOL 1Department of Health and Exercise Science, The College of New Jersey, Ewing, New Jersey 08628; 2Department of Kinesiology; 3Department of Physiology and Neurobiology, The University of Connecticut, Storrs, Connecticut 06269; 4Section of Endocrinology, Diabetes, and Nutrition, Boston University School of Medicine, Boston Medical Center, Boston, MA; 5Department of Kinesiology, Division of Health Sciences, El Camino College, Torrance California; 6Division of Exercise Physiology, Department of Human Performance and Applied Exercise Sciences, West Virginia University, Morgantown, West Virginia 26508; 7Department of Health, Human Performance, and Recreation, Baylor University, Waco, Texas 76798; 8Department of Pediatrics, University of Virginia, Charlottesville, Virginia; and 9Department of Pediatrics, Riley Hospital, Indiana University School of Medicine, Indianapolis, Indiana ABSTRACT the most effective anabolic form of exercise, and over the past Hoffman, JR, Kraemer, WJ, Bhasin, S, Storer, T, Ratamess, NA, 20 years, the research base for resistance exercise has just Haff, GG, Willoughby, DS, and Rogol, AD. Position stand on started to develop to a significant volume of work to help in the Androgen and human growth hormone use. J Strength Cond decision-making process in program design (187,248,305). Res 23(5): S1–S59, 2009—Perceived yet often misunderstood The interface with nutritional strategies has been less studied, demands of a sport, overt benefits of anabolic drugs, and the yet may yield even greater benefits to the individual athlete in inability to be offered any effective alternatives has fueled their attempt to train naturally. Nevertheless, these are the 2 anabolic drug abuse despite any consequences. Motivational domains that require the most attention when trying to optimize interactions with many situational demands including the desire the physical adaptations to exercise training without drug use. for improved body image, sport performance, physical function, Recent surveys indicate that the prevalence of androgen use and body size influence and fuel such negative decisions. among adolescents has decreased over the past 10–15 years Positive countermeasures to deter the abuse of anabolic drugs (154,159,246,253,370,441,493). The decrease in androgen are complex and yet unclear. Furthermore, anabolic drugs work use among these students may be attributed to several factors and the optimized training and nutritional programs needed to related to education and viable alternatives (i.e., sport supple- cut into the magnitude of improvement mediated by drug abuse ments) to substitute for illegal drug use. Although success has require more work, dedication, and preparation on the part of been achieved in using peer pressure to educate high school both athletes and coaches alike. Few shortcuts are available athletes on behaviors designed to reduce the intent to use to the athlete who desires to train naturally. Historically, the androgens (206), it has not had the far-reaching effect desired. NSCA has placed an emphasis on education to help athletes, It would appear that using the people who have the greatest coaches, and strength and conditioning professionals become influence on adolescents (coaches and teachers) be the more knowledgeable, highly skilled, and technically trained in primary focus of the educational program. It becomes imperative their approach to exercise program design and implementation. that coaches provide realistic training goals for their athletes and Optimizing nutritional strategies are a vital interface to help understand the difference between normal physiological cope with exercise and sport demands (516–518). In addition, adaptation to training or that is pharmaceutically enhanced. research-based supplements will also have to be acknowl- Only through a stringent coaching certification program will edged as a strategic set of tools (e.g., protein supplements academic institutions be ensured that coaches that they hire will before and after resistance exercise workout) that can be used have the minimal knowledge to provide support to their athletes in conjunction with optimized nutrition to allow more effective in helping them make the correct choices regarding sport adaptation and recovery from exercise. Resistance exercise is supplements and performance-enhancing drugs. Address correspondence to Jay R. Hoffman, [email protected]. The NSCA rejects the use of androgens and hGH or any performance-enhancing drugs on the basis of ethics, the ideals 23(Supplement 5)/S1–S59 of fair play in competition, and concerns for the athlete’s health. Journal of Strength and Conditioning Research Ó 2009 National Strength and Conditioning Association The NSCA has based this position stand on a critical analysis of VOLUME 23 | SUPPLEMENT 5 | AUGUST 2009 | S1 Androgen and Human Growth Hormone Use the scientific literature evaluating the effects of androgens and 10. Combined administration of hGH and resistance exercise human growth hormone on human physiology and perfor- training is associated with minimal gains in lean body mance. The use of anabolic drugs to enhance athletic mass, muscle size, and maximal voluntary strength in men performance has become a major concern for professional compared with resistance exercise alone. sport organizations, sport governing bodies, and the federal 11. Human growth hormone is approved for the therapy of government. It is the belief of the NSCA that through education children and adolescents with growth hormone de- ficiency, Turner syndrome, small for gestational age with and research we can mitigate the abuse of androgens and hGH failure to catch-up to the normal growth curves, chronic by athletes. Due to the diversity of testosterone-related drugs kidney disease, Prader-Willi syndrome, idiopathic short and molecules, the term androgens is believed to be a more stature, Noonan syndrome, and SHOX gene deletion. For appropriate term for anabolic steroids. adults, hGH is approved for the treatment of GH deficiency, AIDS/HIV with muscle wasting, and short 1. Androgen administration in a concentration-dependent bowel syndrome. manner increases lean body mass, muscle mass, and 12. The magnitude and frequency of adverse events associ- maximal voluntary strength in men. However, the upper ated with hGH use are clearly dose related. Potential concentration for maximum effects remains unknown. adverse events include suppression of the hypothalamic- 2. Combined administration of androgens and resistance pituitary GH/IGF-1 axis, water retention, edema, in- exercise training is associated with greater gains in lean creased intracranial pressure, joint and muscle aches, and body mass, muscle size, and maximal voluntary strength in those of needle injection (hepatitis and HIV/AIDS). men than either intervention alone. These should be the same in women as well as in men. 3. Testosterone therapy is approved only for the treatment 13. Continued effort should be made to educate athletes, of hypogonadism in adolescent and adult men. However, coaches, parents, physicians, and athletic trainers along the anabolic applications of androgens and selective AR with the general public on androgen and hGH use and modulators are being explored for the functional limitations abuse. Educational programs should focus on potential associated with aging and some types of chronic illness. medical risks of these illegal performance-enhancing 4. The magnitude and frequency of adverse effects among drugs use, optimizing training programs and concurrent androgen users have not been systematically studied. nutritional strategies to enhance physiological adaptation Potential adverse effects of androgen use in men include and performance. In addition, educating coaches on suppression of the hypothalamic-pituitary-gonadal axis, setting realistic training goals and expectations for their mood and behavior disorders, increased risk of cardiovascular athletes will help reduce the pressures to use illegal PED disease, hepatic dysfunction with oral androgens, insulin and assist in potentially identifying potential users of resistance, glucose intolerance, acne, gynecomastia, and illegal PED. withdrawal after discontinuation. In addition, the polyphar- 14. The NSCA supports and promotes additional research macy of many androgen users (psychoactive and accessory funding to be directed toward effective educational drugs) may have serious adverse effects of their own. programs, documentation of both acute and long-term 5. The adverse effects of androgen administration in women adverse effects of androgen and hGH abuse, strategies for are similar to those noted in men. In addition, women optimizing athletic performance through training and using androgens may also experience virilizing side effects nutritional interventions, strategies to help athletes such as enlargement of the clitoris, deepening of the voice, discontinue androgen and hGH use, and strategies for hirsutism, and changes in body habitus. These changes the detection of abuse of androgens and hGH. may not be reversible on cessation of androgen use. 6. In pre- and peripubertal children, androgen use may lead to he use of androgens by athletes has received a lot of virilization, premature epiphyseal closure, and resultant attention
Recommended publications
  • The Endocrine System Brightside July, 2019 by Dr
    The Endocrine System Brightside July, 2019 By Dr. Derek Conte How does the body regulate and balance itself from minute to minute, hour to hour and month to month? What is it that allows the food we eat to be utilized for growth, healing and energy? What causes the female egg to drop each month or a mother’s milk to flow? The answer is the endocrine system, which is comprised of the hypothalamus, pituitary gland, pineal gland, thyroid and parathyroid glands, thymus gland, the adrenals, pancreas, ovaries and testes. The brain signals these specialized glands to release hormones to initiate essential chemical actions that sustain life. The word “endocrine” literally means “to cry inside” and that is exactly what happens when the endocrine system works. An example is growth hormone (GH) or somatotropin, responsible for growth and tissue repair. During exercise or when we have low blood sugar or high blood amino acid levels, the hypothalamus leaks (“cries”) growth hormone releasing hormone (GHRH) through very small vessels into the anterior pituitary gland which then leaks growth hormone into the general circulation, acting on cells for growth or replacement of old or damaged tissues. Pro ballplayers looking for an edge have been using growth hormone. The hormone that shuts this process off is called growth hormone inhibiting hormone (GHIH) or somatostatin (“growth stop”), released when blood sugar levels are high. If there ever is an excess of growth hormone, it can result in gigantism or acromegaly depending on whether its onset occurred before or after the growth plates in the bones have closed around the age of 17.
    [Show full text]
  • DHEA | Medchemexpress
    Inhibitors Product Data Sheet DHEA • Agonists Cat. No.: HY-14650 CAS No.: 53-43-0 Molecular Formula: C₁₉H₂₈O₂ • Molecular Weight: 288.42 Screening Libraries Target: Androgen Receptor; Endogenous Metabolite Pathway: Others; Metabolic Enzyme/Protease Storage: Please store the product under the recommended conditions in the Certificate of Analysis. SOLVENT & SOLUBILITY In Vitro DMSO : 50 mg/mL (173.36 mM; Need ultrasonic) Ethanol : 50 mg/mL (173.36 mM; Need ultrasonic) H2O : 1 mg/mL (3.47 mM; Need ultrasonic) Mass Solvent 1 mg 5 mg 10 mg Concentration Preparing 1 mM 3.4672 mL 17.3358 mL 34.6717 mL Stock Solutions 5 mM 0.6934 mL 3.4672 mL 6.9343 mL 10 mM 0.3467 mL 1.7336 mL 3.4672 mL Please refer to the solubility information to select the appropriate solvent. In Vivo 1. Add each solvent one by one: Cremophor EL Solubility: 14.29 mg/mL (49.55 mM); Clear solution; Need ultrasonic 2. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (8.67 mM); Clear solution 3. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (8.67 mM); Clear solution 4. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (8.67 mM); Clear solution 5. Add each solvent one by one: 10% EtOH >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (8.67 mM); Clear solution 6.
    [Show full text]
  • Growth Hormone Booklet
    GROWTH HORMONE AND PRADER-WILLISECOND EDITION SYNDROME A REFerence For FaMILies and Care ProViders Donald G. Goranson, Jr., Editor Growth Hormone and Prader-Willi Syndrome — Second Edition Published By: Prader-Willi Syndrome Association (Usa) 8588 Potter Park Drive, Suite 500 Sarasota, Florida 34238 Toll Free: 800-926-4797 Local: 941-312-0400 Fax: 941-312-0142 www.pwsausa.org © Copyright 2011 A Reference for Families and Care Providers Growth HORMONE AND PraderSECOND-WILLI EDITION Syndrome A REFerence For FaMILies and Care ProViders Donald G. Goranson, Jr., Editor Growth Hormone and Prader-Willi Syndrome — Second Edition A Reference for Families and Care Providers CONTENTS Acknowledgments....................................................................... 5 Introduction and History .............................................................. 7 Prader-Willi Syndrome and Growth ...................................................... 9 Effects of Growth Hormone Treatment in Children with PWS ................................ 20 What Is Involved in Growth Hormone Treatment? .......................................... 26 Questions, Wisdom and Survey Data from our Families ..................................... 34 Appendix: A. Overview of Prader-Willi Syndrome................................................ 40 B. Information Resources on Prader-Willi Syndrome .................................... 42 C. Information Resources on Growth Hormone Use and Products ........................ 43 D. Glossary of Terms ............................................................
    [Show full text]
  • Testosterone, Or
    COSI SIMILI, COSI DIVERSE 1. FOR A FEW ATOMS MORE: TESTOSTERONE AND DOPING A few days ago, the Tour de France winner, Floyd Landis, was found to have a high, indeed impermissible level of testosterone in his urine. Not quite, more of what was actually found in just a while. The sample was taken just after his comeback victory in a critical stage of bicycling’s premier race. If a second sample confirms the problem, Landis’s victory will be disallowed. Testosterone is the principal male sex hormone, produced mainly where… you might suspect from its name. And it is also produced in the ovaries of females. Testosterone is a so-called anabolic steroid, a class of molecules that give us a continuing lesson that almost the same is not the same. All the steroids, the class of molecules that include testosterone, have the same atomic framework – four all-carbon rings, fused together. Three are hexagons, the third ring going off at an angle to the other two. Fused to that last ring is a pentagon of carbon atoms. Call the rings A (6 carbons), B (6), C (6), D (5). Testosterone has an oxygen and a hydrogen (OH) attached to ring D, two CH3 (methyl) groups, one at the juncture of rings C and D, the other at the juncture of A and B. Finally ring A of testosterone has an oxygen attached to it as well, and there is a double bond in that ring. testosterone Testosterone is responsible for the secondary sex changes which occur in male puberty – facial and pubic hair, oiliness of skin, body odor, all that teenage boy stuff.
    [Show full text]
  • Endobj 21 0 Obj <>/Filter/Flatedecode/ID[]/Index[16 7]
    %PDF-1.4 %âãÏÓ 16 0 obj <> endobj 21 0 obj <>/Filter/FlateDecode/ID[]/Index[16 7]/Info 15 0 R/Length 36/Prev 1529327/Root 17 0 R/Size 23/Type/XRef/W[1 2 0]>>stream hÞbbd`b`r`b`cb`>stream hÞb```f``âc```‘¨`b@ ›…£éœÌ®5zà $À Å 9 Â Ü Ì‚`.ƒlÕ ÍÄ÷ ,"† endstream endobj 17 0 obj < > endobj 18 0 obj < >>>/Rotate 0/Type/Page>> endobj 19 0 obj <>stream H‰*ä234Ò300P AsK;9—KßËÓ0QÁ%Ÿ+ À H endstream endobj 20 0 obj <>stream ÿØÿà JFIF È È ÿþ Business Office Q76ÿÛ C $.' ",#(7),01444'9=82 À@ú– ~5â¾Óµï‰V%Õ ¢¾bø‡ã?xKÄ_Ùñj:eŵÄms{24.@C†ÁÇ=ý+¼ø[©ø¯Äš$ö©`±]G †Ö;6R¤6ÕvmÜò§ØõôsØh¯– •êž ¿ñ^»áØuBïKI/ao Z>"ç†cæ|Û‡8ã¿jzògˆþ+øÓ@ÖõM"{- å°+—Xåë.å#çãå#ŽÕêi?Ål’æðƒ»¨qûHÊ‘‘ϯ·Oz ö +Ç>xÇÄ>!ÕuÍ+Äz]¶Ÿw¦y@Çs—Üy%ˆ# G-7âÄ;ZÓ|1 Yï_°&b"…OBøç=ñè3ée¢¼CRÔ¾&øvÖãT»³Ðµ»X†ù-,|ØfUï³ çŽÇ'Ž3W-|}zÿ ÛÆ’Ù[›¡È-ÑÎÎ%(y= 'ß=(Øè¯ “Åß`ðôÚÝÏ„´ûh¡·7פJ.âJcƒŒü¤‚:ž+šðïÅÏxŠþ?Mð½¬×2De ÞìF2yâ€>š¢¼'Dñ÷Šçñm—†õ¿ G¥És ²¬†äJ¬ e㨠ã$dqYÞ$ø¥¯x_UþËÕü5l&h„ÑIoz]$L‘JÔt#4ô=àº7|q¬é°ê–>Žk)”¼nº¤`°=½+sÁ?/ øRÞI"›ÄºLrFþ[£^F ·Lc=³Ï§9èk¯R òï@EPEPEPEPETº½µ³]×W0À¾²È~µ–«§_ŒÙ_ÚÜŒ•ýÌÊüœp}(JŠ¨·¶¬$+s ¹ŽB$#ÿ túGñsé Š( Š( Š( Š( Š( Š( Š( Š( Š( Š( Š( Š( Š( Š( Š( Š( Š( Š( Š( Š( Š( Š( Š( Š( Š( Š( Š( Š( Š( Š( Š( Š( Š( Š( Š( Š( Š( Š( Š( Š( Š( Š( Š( Š( Š( Š( Š( Š( Š( Š( Š( Š( Š( Š( Š( Š( Š( Š( Š( Š( Š( Š( Š( Š( Š( Š( Š( Š( çŠ9âxe@ñÈ¥]OBWç¼2Kðãâ@ÌB(¬oXÚyläóŽçc{ãÒ¿C+äoÚKI÷ºv¸‘'…¬å9Ç –_ǹö Kø¼÷$¶²ðfñ5Î-ܼÊ$1 ë’äç½|ýð_þÈñݧÚTEöøÛO™U—pÛ‘žà~ ¯qø §_Ë£jÓ šÑ¼Ï|EÕuR]´ý¦Û÷~ÐØy˜¹bžÄc-Mñ´ð÷Yʆâƒÿ ]’´þxrO xVÎÎá¦kÙ³svf}Íç>dþúu=k7ãgü“ícþØÿ èä gÍ¿ üa£ø3YÕoµ‰fQ-š¬1Åv•ƒg°?\z÷ÿ ƒZ™ñW†5;ûÍÒ¥ö¥rÍœ…FƯ@§åßbŽãÄ:äSD²Fl£R®¡•cAîü4 ¦¿=|[á]KÀ¾3ÒìÅóÊ%Ó0p~Àÿ úz'Â?hžÑ-nuÍ6ˆ¡"H¤»]öê
    [Show full text]
  • The Effects of Androgens and Antiandrogens on Hormone Responsive Human Breast Cancer in Long-Term Tissue Culture1
    [CANCER RESEARCH 36, 4610-4618, December 1976] The Effects of Androgens and Antiandrogens on Hormone responsive Human Breast Cancer in Long-Term Tissue Culture1 Marc Lippman, Gail Bolan, and Karen Huff MedicineBranch,NationalCancerInstitute,Bethesda,Maryland20014 SUMMARY Information characterizing the interaction between an drogens and breast cancer would be desirable for several We have examined five human breast cancer call lines in reasons. First, androgens can affect the growth of breast conhinuous tissue culture for andmogan responsiveness. cancer in animals. Pharmacological administration of an One of these cell lines shows a 2- ho 4-fold stimulation of drogens to rats bearing dimathylbenzanthracene-induced thymidina incorporation into DNA, apparent as early as 10 mammary carcinomas is associated wihh objective humor hr following androgen addition to cells incubated in serum regression (h9, 22). Shionogi h15 cells, from a mouse mam free medium. This stimulation is accompanied by an ac many cancer in conhinuous hissue culture, have bean shown celemation in cell replication. Antiandrogens [cyproterona to be shimulatedby physiological concentrations of andro acetate (6-chloro-17a-acelata-1,2a-methylena-4,6-pregna gen (21), thus suggesting that some breast cancer might be diene-3,20-dione) and R2956 (17f3-hydroxy-2,2,1 7a-tnima androgen responsive in addition to being estrogen respon thoxyastra-4,9,1 1-Inane-i -one)] inhibit both protein and siva. DNA synthesis below control levels and block androgen Evidence also indicates that tumor growth in humans may mediahed stimulation. Prolonged incubahion (greahenhhan be significantly altered by androgens. About 20% of pahianhs 72 hn) in antiandrogen is lethal.
    [Show full text]
  • CASODEX (Bicalutamide)
    HIGHLIGHTS OF PRESCRIBING INFORMATION • Gynecomastia and breast pain have been reported during treatment with These highlights do not include all the information needed to use CASODEX 150 mg when used as a single agent. (5.3) CASODEX® safely and effectively. See full prescribing information for • CASODEX is used in combination with an LHRH agonist. LHRH CASODEX. agonists have been shown to cause a reduction in glucose tolerance in CASODEX® (bicalutamide) tablet, for oral use males. Consideration should be given to monitoring blood glucose in Initial U.S. Approval: 1995 patients receiving CASODEX in combination with LHRH agonists. (5.4) -------------------------- RECENT MAJOR CHANGES -------------------------- • Monitoring Prostate Specific Antigen (PSA) is recommended. Evaluate Warnings and Precautions (5.2) 10/2017 for clinical progression if PSA increases. (5.5) --------------------------- INDICATIONS AND USAGE -------------------------- ------------------------------ ADVERSE REACTIONS ----------------------------- • CASODEX 50 mg is an androgen receptor inhibitor indicated for use in Adverse reactions that occurred in more than 10% of patients receiving combination therapy with a luteinizing hormone-releasing hormone CASODEX plus an LHRH-A were: hot flashes, pain (including general, back, (LHRH) analog for the treatment of Stage D2 metastatic carcinoma of pelvic and abdominal), asthenia, constipation, infection, nausea, peripheral the prostate. (1) edema, dyspnea, diarrhea, hematuria, nocturia, and anemia. (6.1) • CASODEX 150 mg daily is not approved for use alone or with other treatments. (1) To report SUSPECTED ADVERSE REACTIONS, contact AstraZeneca Pharmaceuticals LP at 1-800-236-9933 or FDA at 1-800-FDA-1088 or ---------------------- DOSAGE AND ADMINISTRATION ---------------------- www.fda.gov/medwatch The recommended dose for CASODEX therapy in combination with an LHRH analog is one 50 mg tablet once daily (morning or evening).
    [Show full text]
  • Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals
    Journal of Clinical Medicine Review Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals Carlotta Cocchetti 1, Jiska Ristori 1, Alessia Romani 1, Mario Maggi 2 and Alessandra Daphne Fisher 1,* 1 Andrology, Women’s Endocrinology and Gender Incongruence Unit, Florence University Hospital, 50139 Florence, Italy; [email protected] (C.C); jiska.ristori@unifi.it (J.R.); [email protected] (A.R.) 2 Department of Experimental, Clinical and Biomedical Sciences, Careggi University Hospital, 50139 Florence, Italy; [email protected]fi.it * Correspondence: fi[email protected] Received: 16 April 2020; Accepted: 18 May 2020; Published: 26 May 2020 Abstract: Introduction: To date no standardized hormonal treatment protocols for non-binary transgender individuals have been described in the literature and there is a lack of data regarding their efficacy and safety. Objectives: To suggest possible treatment strategies for non-binary transgender individuals with non-standardized requests and to emphasize the importance of a personalized clinical approach. Methods: A narrative review of pertinent literature on gender-affirming hormonal treatment in transgender persons was performed using PubMed. Results: New hormonal treatment regimens outside those reported in current guidelines should be considered for non-binary transgender individuals, in order to improve psychological well-being and quality of life. In the present review we suggested the use of hormonal and non-hormonal compounds, which—based on their mechanism of action—could be used in these cases depending on clients’ requests. Conclusion: Requests for an individualized hormonal treatment in non-binary transgender individuals represent a future challenge for professionals managing transgender health care. For each case, clinicians should balance the benefits and risks of a personalized non-standardized treatment, actively involving the person in decisions regarding hormonal treatment.
    [Show full text]
  • Fluoxymesterone-Dea Schedule Iii Androfluorene
    Cat. No. F7751 FLUOXYMESTERONE--DEA SCHEDULE III ANDROFLUORENE Androgen. OH Mol. Formula: C20H29FO3 HO H3C CH3 Mol. Wt.: 336.45 (anhyd.) F H3C m.p.: 288-290°C CAS Registry No.: 76-43-7 O Chemical Name: 4-Androsten-9a-fluoro-17a-methyl-11b,17b-diol-3-one 22 Physical Properties: White photosensitive solid. [a] D = +102.34° (c = 0.47, EtOH). Caution: Due care should be exercised to prevent skin contact, ingestion or inhalation of this compound. Storage: Store tightly sealed at room temperature, protected from exposure to light. Solubility: Soluble in ethanol (7.3 mg/ml) or water (< 0.5 mg/ml). Solubility in 45% aqueous (w/v) 2-hydroxypropyl-b- cyclodextrin (Cat. No. H-107): 6.4 mg/ml. Disposal: Dissolve or mix the compound with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber. This product is controlled by the Drug Enforcement Administration. Appropriate security must be maintained until the substance is destroyed. Records must be kept which detail the ultimate disposition of the material. References: 1. Merck Index 11th Ed., No. 4113. 2. Saborido, A., Vila, J., Molano, F., Megias, A. “Effect of steroids on mitochondria and sarcotubular system of skeletal muscle.” J. Appl. Physiol. 70(3), 1038 (1991). 3. Fernandez, L., Chirino, R., Boada, L.D., Navarro, D., Cabrera, N., del Rio, I., Diaz-Chico, B.N. “Stanozolol and danazol, unlike natural androgens, interact with the low affinity glucocorticoid-binding sites from male rat liver microsomes.” Endocrinology 134(3), 1401 (1994). CONTROLLED SUBSTANCE - DEA LICENSE REQUIRED (III) Rev.
    [Show full text]
  • 5 Part 1300—Definitions
    PART 1300—DEFINITIONS (7) 5-androstenediol (3b,17b-dihydroxy- androst-5-ene) Sec. (8) 1-androstenedione ([5a]-androst-1- 1300.01 Definitions relating to controlled en-3,17-dione) substances. (9) 4-androstenedione (androst-4-en- 1300.02 Definitions relating to listed chemi- 3,17-dione) cals. (10) 5-androstenedione (androst-5-en- 1300.03 Definitions relating to electronic or- 3,17-dione) ders for controlled substances and elec- tronic prescriptions for controlled sub- (11) bolasterone (7a,17a-dimethyl-17b- stances. hydroxyandrost-4-en-3-one) 1300.04 Definitions relating to the dis- (12) boldenone (17b-hydroxyandrost-1,4- pensing of controlled substances by diene-3-one) means of the Internet. (13) boldione (androsta-1,4-diene-3,17- 1300.05 Definitions relating to the disposal dione) of controlled substances. (14) calusterone (7b,17a-dimethyl-17b- AUTHORITY: 21 U.S.C. 802, 821, 822, 829, hydroxyandrost-4-en-3-one) 871(b), 951, 958(f). (15) clostebol (4-chloro-17b- SOURCE: 62 FR 13941, Mar. 24, 1997, unless hydroxyandrost-4-en-3-one) otherwise noted. (16) dehydrochloromethyltestosterone (4-chloro-17b-hydroxy-17a-methyl- § 1300.01 Definitions relating to con- androst-1,4-dien-3-one) trolled substances. (17) desoxymethyltestosterone (17a- (a) Any term not defined in this part methyl-5a-androst-2-en-17b-ol) shall have the definition set forth in (a.k.a. ‘madol‘) section 102 of the Act (21 U.S.C. 802), (18) D1-dihydrotestosterone (a.k.a.‘1- except that certain terms used in part testosterone‘) (17b-hydroxy-5a- 1316 of this chapter are defined at the androst-1-en-3-one) beginning of each subpart of that part.
    [Show full text]
  • Criteria to Indicate Testosterone Administration
    Br. J. Sp. Med; Vol 24, No. 4 Br J Sports Med: first published as 10.1136/bjsm.24.4.253 on 1 December 1990. Downloaded from Criteria to indicate testosterone administration A.T. Kicman1, R.V. Brooks2, S.C. Collyere, D.A. Cowan', M.N. Nanjee2, G.J. Southan2 and M.J. Wheelee 'Drug Control and Teaching Centre, King's College, London University 2Department of Chemical Pathology, UMDS, London University A detection method for testosterone administration was was found to increase after an intramuscular injection developed using radioimmunoassay to measure the of testosterone heptanoate in all ten normal males, urinary ratios of testosterone (T) to epitestosterone (E) and although there was an overlap between the basal to luteinizing hormone (LH). A comparative study of the range and that obtained three days after injection. effect on these ratios of a single intramuscular injection of testosterone heptanoate followed by stimulation with The method used was radioimmunoassay as protein human chorionic gonadotrophin (HCG) in three normal hormones cannot be measured by gas liquid chroma- men was undertaken. To allow immediate investigation, a tography-mass spectrometry (GLC-MS). commercially supplied epitestosterone antiserum was In 1983, the International Olympic Committee used. This study showed that both T/E and T/LH ratios (IOC) adopted the ratio of urinary testosterone to could be used to detect testosterone administration, the epitestosterone (T/E) as the sole test for testosterone latter also being an indicator of HCG use due to doping as both these hormones could be convenient- cross-reactivity with the LH antiserum. Subsequently, an ly measured by GLC-MS.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]